HBM Holdings Limited (02142.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.5x

Market Cap

HKD 11.65B

MomentumView details →

1D Return

−2.52%

YTD Return

+21.05%

RSI (14)

51.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.5x

Market Cap

HKD 11.65B

RSI (14)

51.7

MomentumView details →

1D Return

−2.52%

YTD Return

+21.05%

ProfitabilityView details →

Gross Margin

92.20%

Net Margin

49.83%

EBITDA Margin

47.45%

ROE (TTM)

29.10%

ROA (TTM)

22.80%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

+93.31%

EPS YoY

+360.21%

FCF YoY

+258.70%

Revenue CAGR 3Y

+57.29%

EPS CAGR 3Y

+97.71%

EBITDA YoY

+580.27%

EarningsView details →

EPS (Actual)

HKD 0.63

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

0.18%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

4.90x

Quick Ratio

4.84x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

244.02M

Net Income (TTM)

121.59M

Op. CF (TTM)

—

Next earningsMar 31, 2027 →

Latest newsMore news →

Harbour BioMed announced its interim results for the six months ended June 2026, with revenue of $122 million, up 20.9% year-on-year, and net profit of $64.88 million, down 9.5%.8d ago

China's National Medical Products Administration approved Harbour BioMed's IND application for HBM7004, a novel B7H4xCD3 bispecific antibody for advanced solid tumors, following prior FDA approval for a US Phase I trial.18d ago

Similar companies

诺唯赞688105.SH Duality Biotherapeutics, Inc.09606.HK Mabwell-b02493.HK Bio-Techne CorporationTECH 欧林生物688319.SH Suzhou Ribo Life Science Co06938.HK Find similar companies →

Latest newsMore news →

Harbour BioMed announced its interim results for the six months ended June 2026, with revenue of $122 million, up 20.9% year-on-year, and net profit of $64.88 million, down 9.5%.8d ago China's National Medical Products Administration approved Harbour BioMed's IND application for HBM7004, a novel B7H4xCD3 bispecific antibody for advanced solid tumors, following prior FDA approval for a US Phase I trial.18d ago